1675 studies found for:    Squamous Cell Carcinoma
Show Display Options
Rank Status Study
1 Completed
Has Results
Correlation Between Skin Carotenoid Levels and Previous History of Skin Cancer
Conditions: Skin Cancer;   Basal Cell Carcinoma;   Squamous Cell Carcinoma
Intervention:
2 Unknown  The Character of Perfusion Parameters Derived From MDCT Between Adenocarcinoma and Squamous Cell Carcinoma of Lung in the Treatment Course of Radiation Therapy
Conditions: Adenocarcinoma;   Squamous Cell Carcinoma;   Relevant Condition Terms to the Conditions Field
Intervention: Radiation: CT, radiation therapy
3 Completed A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
Conditions: HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma;   HER2 + Breast Cancer;   HER2 + Gastric Cancer;   Squamous Cell Carcinoma of Head and Neck;   Esophageal Squamous Cell Carcinoma
Intervention: Drug: LJM716
4 Recruiting Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Middle or Lower Thoracic Esophageal Squamous Cell Carcinoma
Condition: Locally Advanced Thoracic Middle-lower Segment Esophageal Squamous Cell Carcinoma
Interventions: Radiation: preoperative radiotherapy;   Drug: cetuximab
5 Recruiting Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Oral Cavity Squamous Cell Carcinoma;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer;   Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions: Drug: sorafenib tosylate;   Drug: cisplatin;   Drug: docetaxel;   Other: Correlative Studies
6 Recruiting A Pilot for a Case-Control Study of Esophageal Squamous Cell Carcinoma in Western Kenya
Condition: Esophageal Squamous Cell Carcinoma
Intervention:
7 Active, not recruiting Oral Rigosertib for Squamous Cell Carcinoma
Conditions: Head and Neck Squamous Cell Carcinoma;   Anal Squamous Cell Carcinoma;   Lung Squamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Esophageal Squamous Cell Carcinoma
Intervention: Drug: rigosertib
8 Not yet recruiting Aggressive Squamous Cell Carcinoma in Organ Transplant Recipients
Condition: Squamous Cell Carcinoma
Intervention:
9 Recruiting TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma
Conditions: Stage III Oral Cavity Squamous Cell Carcinoma;   Stage IVA Oral Cavity Squamous Cell Carcinoma
Intervention: Drug: TPF induction chemotherapy
10 Enrolling by invitation Comparison of Morphometric Assessment Using Methyl Green Pyronin and AgNOR Staining of Oral Squamous Cell Carcinoma
Conditions: Oral Squamous Cell Carcinoma;   Oral Epithelial Dysplasia
Intervention:
11 Terminated Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma
Condition: Squamous Cell Carcinoma
Interventions: Drug: Tarceva, Torisel;   Drug: 28-day cycles of Tarceva 150 mg by mouth daily and Torisel 15 mg IV weekly
12 Completed Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Conditions: Squamous Cell Carcinoma;   Carcinoma of Head/Neck
Interventions: Drug: Taxotere;   Drug: Cisplatin;   Drug: 5-Fluorouracil;   Drug: Leucovorin;   Drug: G-CSF;   Drug: Ciprofloxacin
13 Unknown  Efficacy Comparison Study of Combination Regimens to Treat Advanced Esophageal Squamous Cell Carcinoma
Conditions: First Line Chemotherapy;   Capecitabine Plus Cisplatin Versus Capecitabine Plus Paclitaxel;   Advanced or Recurrent Esophageal Squamous Cell Carcinoma
Intervention: Drug: Capecitabine plus cisplatin(XP) versus capecitabine plus paclitaxel(XT)
14 Recruiting Identification of Breath Biomarkers in Head and Neck Squamous Cell Carcinoma
Conditions: Oral Cavity Squamous Cell Carcinoma;   Oropharyngeal Squamous Cell Carcinoma
Intervention:
15 Active, not recruiting Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma
Condition: Head and Neck Squamous Cell Carcinoma
Interventions: Drug: Erlotinib;   Drug: Erlotinib plus sulindac;   Drug: Placebo
16 Active, not recruiting A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell Carcinoma
Condition: Head and Neck Squamous Cell Carcinoma
Intervention: Drug: PF-00299804
17 Active, not recruiting Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC
Conditions: Squamous Cell Carcinoma;   Non-Small Cell Lung Cancer
Intervention: Drug: Erlotinib + Rosuvastatin
18 Not yet recruiting Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the Oral Cavity
Conditions: Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage I Squamous Cell Carcinoma of the Oropharynx;   Stage I Verrucous Carcinoma of the Oral Cavity;   Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage II Squamous Cell Carcinoma of the Oropharynx;   Stage II Verrucous Carcinoma of the Oral Cavity;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity
Interventions: Drug: HPPH;   Device: Light Infusion Therapy™;   Procedure: therapeutic conventional surgery
19 Recruiting Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma
Condition: Squamous Cell Carcinoma
Interventions: Drug: Nedaplatin;   Drug: Cisplatin;   Drug: Docetaxel
20 Unknown  Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma
Condition: Local Advanced Esophageal Squamous Cell Carcinoma
Interventions: Drug: Placebo, Radiotherapy and Chemotherapy;   Drug: Nimotuzumab, Radiotherapy and Chemotherapy

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years